uniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 164,429 Shares

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 164,429 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the completion of the sale, the chief executive officer owned 558,810 shares of the company’s stock, valued at approximately $24,766,459.20. The trade was a 22.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Trading Down 4.1%

Shares of NASDAQ:QURE opened at $44.39 on Tuesday. The stock has a 50 day moving average of $25.30 and a 200 day moving average of $22.30. The company has a market cap of $2.80 billion, a PE ratio of -12.76 and a beta of 0.98. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, equities research analysts expect that uniQure N.V. will post -3.64 EPS for the current year.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently modified their holdings of QURE. Vanguard Group Inc. grew its holdings in shares of uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after purchasing an additional 152,417 shares in the last quarter. Aberdeen Group plc raised its stake in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares in the last quarter. Quinn Opportunity Partners LLC purchased a new stake in uniQure during the third quarter valued at $6,281,000. Farallon Capital Management LLC lifted its position in uniQure by 3,935.7% during the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after purchasing an additional 551,000 shares during the last quarter. Finally, Boone Capital Management LLC bought a new position in uniQure during the third quarter valued at $8,599,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $15.00 to $60.00 in a research note on Monday, March 9th. The Goldman Sachs Group increased their price target on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research note on Thursday. Wolfe Research initiated coverage on uniQure in a report on Monday, February 23rd. They set a “peer perform” rating on the stock. HC Wainwright restated a “buy” rating on shares of uniQure in a research report on Thursday. Finally, TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $58.92.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported initial AMT-260 data in temporal lobe epilepsy showing meaningful seizure reductions in early patients, with no treatment-related serious adverse events, which supports the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Early trial updates also highlighted seizure reductions of 79% to 100% in three patients, reinforcing investor optimism around AMT-260’s potential. Article Title
• Neutral Sentiment: The company also announced preliminary data from the first cohort in its Phase I/IIa AMT-260 clinical trial, a routine but important catalyst for a development-stage biotech. Article Title
• Negative Sentiment: uniQure announced a $150 million underwritten public offering, with an additional $22.5 million greenshoe option, which could dilute existing shareholders even if it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may also weigh on sentiment, even though the transactions were made under pre-arranged 10b5-1 plans. Article Title

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.